



SEQUENCE LISTING

<110> SAIKAWA, Akira  
IGARI, Yasutaka  
HATA, Yoshio  
YAMAMOTO, Kazumichi

<120> Sustained-Release Composition, Method of its Preparation and Use Thereof

<130> 2500US1P  
<140> 10/799,320  
<141> 2004-03-12

<150> 09/582,926  
<151> 2000-07-05

<150> PCT/JP99/00086  
<151> 1999-01-13

<150> JP 10-6412  
<151> 1998-01-16

<160> 5

<170> PatentIn version 3.0

<210> 1  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> LH-RH derived peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> 5-oxo-Pro carboxy terminal

<220>  
<221> MOD\_RES  
<222> (6)..(6)  
<223> DLeu, DAla, DTrp, DSer(tbut), D2Nal or Dhis(ImBzl)

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> NH-C2H5 or Gly-NH2

<400> 1

Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa  
1 5 10

<210> 2  
 <211> 11  
 <212> PRT  
 <213> artificial sequence  
  
 <220>  
 <223> LH-RH antagonist derivatives  
  
 <220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> N(4H2-furoyl)Gly or NAc  
  
 <220>  
 <221> MOD\_RES  
 <222> (2)..(2)  
 <223> X is D2Nal  
  
 <220>  
 <221> MOD\_RES  
 <222> (3)..(3)  
 <223> X is D4ClPhe  
  
 <220>  
 <221> MOD\_RES  
 <222> (4)..(4)  
 <223> X is D3Pal  
  
 <220>  
 <221> MOD\_RES  
 <222> (6)..(6)  
 <223> NMeTyr, Tyr, Aph(Atz) or NMeAph(Atz)  
  
 <220>  
 <221> MOD\_RES  
 <222> (7)..(7)  
 <223> DLys(Nic), DCit, DLys(AzaGlyNic),  
  
 <220>  
 <221> MOD\_RES  
 <222> (7)..(7)  
 <223> DLys(AzaGlyFur), DhArg(Et2), DAph(Atz), or DhC  
  
 <220>  
 <221> MOD\_RES  
 <222> (9)..(9)  
 <223> Lys(Nisp), Arg or HArg(Et2)  
  
 <220>

<221> MOD\_RES  
<222> (11)..(11)  
<223> X is DAlaNH2

<400> 2

Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa  
1 5 10

<210> 3  
<211> 8  
<212> PRT  
<213> artificial sequence

<220>  
<223> LH-RH derived peptides

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> 5-oxo-Pro carboxy terminal

<220>  
<221> MOD\_RES  
<222> (6)..(6)  
<223> X is DLeu

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Pro-NH-C2H5 amino terminal

<400> 3

Pro His Trp Ser Tyr Xaa Arg Pro  
1 5

<210> 4  
<211> 11  
<212> PRT  
<213> artificial sequence

<220>  
<223> LH-RH derived peptides

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> N-(S)-tetrahydrofur-2-oyl-Gly

<220>

<221> MOD\_RES  
<222> (2)..(2)  
<223> X is D2Nal

<220>  
<221> MOD\_RES  
<222> (3)..(3)  
<223> X is D4ClPhe

<220>  
<221> MOD\_RES  
<222> (4)..(4)  
<223> X is D3Pal

<220>  
<221> MOD\_RES  
<222> (6)..(6)  
<223> X is NMeTyr

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> X is DLys(Nic)

<220>  
<221> MOD\_RES  
<222> (9)..(9)  
<223> X is Lys(Nisp)

<220>  
<221> MOD\_RES  
<222> (11)..(11)  
<223> X is DAlaNH2

<400> 4

Gly Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa  
1 5 10

<210> 5  
<211> 9  
<212> PRT  
<213> artificial sequence

<220>  
<223> LH-RH derived peptides

<220>  
<221> MOD\_RES  
<222> (1)..(1)

<223> 5-oxo-Pro carboxy terminal

<220>

<221> MOD\_RES

<222> (6)..(6)

<223> X is DLeu

<220>

<221> MOD\_RES

<222> (9)..(9)

<223> Pro-NH-C2H5 amino terminal

<400> 5

Pro His Trp Ser Tyr Xaa Leu Arg Pro  
1 5